Castor分支型支架开窗改造治疗主动脉弓疾病的早期经验
本研究评估分支型支架联合开窗胸主动脉腔内修复(TEVAR)治疗主动脉弓病变的安全性与可行性。2020年7月至2022年11月3家三级医院共21例患者,技术成功率95.2%(20/21),30天死亡率4.8%(1/21)。作者认为该联合策略对特定主动脉弓病变是可行方案,但需进一步研究评估远期耐久性与风险。
要点
- 21例主动脉弓病变患者行分支型支架联合开窗TEVAR,技术成功率95.2%(20/21)。
- 30天死亡率4.8%(1/21),1例卒中经内科治疗反应良好。
- 随访中1例死亡(4.8%)与主动脉并发症相关,靶分支动脉未见闭塞。
核心结论
- 作者认为分支型支架联合开窗TEVAR是处理主动脉弓特定病变的可行策略。
- 作者指出初期结果令人鼓舞,但需进一步研究评估远期耐久性及支架移位、晚期内漏等风险。
研究设计与样本
- 研究为队列研究,纳入2020年7月至2022年11月3家三级医院收治的主动脉弓病变患者21例(平均年龄61.0±14.8岁)。
- 技术成功定义为支架精确释放、分支血管通畅及无I型内漏;次要结局为并发症与全因死亡。
主要发现
- 病变包括主动脉夹层8例、主动脉瘤8例、假性动脉瘤1例、壁内血肿1例、穿透性主动脉溃疡3例。
- 技术成功率为95.2%(20/21),1例失败因术中I型内漏,追加支架后纠正。
- 30天死亡率为4.8%(1/21);1例发生卒中,经内科干预反应良好;中位住院时间10.9±5.4天。
- 随访期间1例死亡(4.8%)与主动脉并发症相关;观察到1例II型内漏并密切监测处理。
- 2例分别因逆行性A型夹层和支架移位接受再干预;靶分支动脉未见闭塞。
临床怎么用
- 作者认为该联合策略为不适合开放手术的患者提供了可行替代,尤其适用于复杂主动脉弓病例。
- 作者指出需进一步研究评估远期耐久性及支架移位、晚期内漏等风险,以确保该技术长期安全有效。
局限性
- 原文在结论与临床影响部分指出,尽管初期结果令人鼓舞,仍需进一步研究评估远期耐久性及支架移位、晚期内漏等风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to assess the safety and viability of combining branched stent graft with fenestrated thoracic endovascular aortic repair (TEVAR) in treating aortic arch lesions. MATERIALS AND METHODS: The cohort included patients presenting with aortic arch lesions who underwent treatment with a combination of branched stent graft and fenestrated TEVAR between July 2020 and November 2022. Technical success was defined as the precise deployment of the stent graft, maintenance of branch vessel patency, and the absence of type I endoleak. The secondary outcomes examined were complications and all-cause mortality. RESULTS: The study cohort comprised 21 patients (average age: 61.0±14.8 years) with aortic arch lesions from 3 tertiary care hospitals. The aortic arch lesions encompassed aortic dissection (N=8), aortic aneurysm (N=8), pseudoaneurysm (N=1), intramural hematoma (N=1), and penetrating aortic ulcer (N=3). The technical success rate achieved was 95.2% (20/21). Failure in one case was due to an intraoperative type I endoleak, which was rectified with an additional stent graft placement. The 30-day mortality rate was 4.8% (1/21). One patient suffered a stroke but responded well to medical intervention. The median hospital stay was 10.9±5.4 days. During the follow-up period, one death (4.8%) was associated with aortic complications. A type II endoleak was observed and managed with close monitoring. Two patients underwent re-interventions for retrograde type A dissection and stent migration, respectively. No occlusions were observed in the target branch arteries. CONCLUSIONS: The combination of branched stent graft with fenestrated TEVAR emerges as a viable strategy for addressing specific lesions in the aortic arch.Clinical ImpactThis study demonstrates the feasibility of using branched stent grafts with fenestrated TEVAR for treating aortic arch lesions, achieving a technical success rate of 95.2%. Compared to traditional open surgery, this innovative, minimally invasive approach reduces perioperative mortality and complications, such as stroke and spinal cord ischemia. For clinicians, it offers a viable alternative for patients unfit for open repair, particularly in complex aortic arch cases. While the initial outcomes are promising, further research is needed to assess long-term durability and risks, including stent graft migration and late endoleak, ensuring the technique's safety and efficacy over time.
引用
- Zeng Z, Huo W, Li T, et al. Early Experience With Fenestration Modification of Castor Branched Stent-Graft for Aortic Arch Diseases. J Endovasc Ther. 2024. PMID: 39315633. doi:10.1177/15266028241280507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。